Oramed Pharmaceuticals Inc.
DE ˙ DB ˙ US68403P2039
3,24 € ↓ -0,02 (-0,77%)
2026-06-05
DEL PRIS
SecurityDE:OJU1 / Oramed Pharmaceuticals Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership158,209 shares
Latest Disclosed Value $ 537,735
Dimensional Fund Advisors Lp reports 5.14% increase in ownership of OJU1 / Oramed Pharmaceuticals Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 158,209 shares of Oramed Pharmaceuticals Inc. (DE:OJU1) valued at $446,940 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 150,471 shares of Oramed Pharmaceuticals Inc.. This represents a change in shares of 5.14% during the quarter. The current value of the position is $512,597 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 158,209 7,738 5.14 538 25.47 0.0000
2026-02-12 2025-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 150,471 2,984 2.02 429 10.03 0.0001
2025-11-12 2025-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 147,487 -19,412 -11.63 389 3.73 0.0001
2025-08-12 2025-06-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 166,899 25,818 18.30 376 24.58 0.0001
2025-05-13 2025-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 141,081 22,086 18.56 302 4.88 0.0001
2025-02-13 2024-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 118,995 70,190 143.82 288 141.18 0.0001
2024-11-07 2024-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 48,805 17,335 55.08 119 48.75 0.0000
2024-08-09 2024-06-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 31,470 10,774 52.06 81 33.33 0.0000
2024-05-10 2024-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 20,696 20,696 60 0.0000
2024-02-07 2023-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 0 -27,285 -100.00 0 -100.00
2023-11-09 2023-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 27,285 27,285 71 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.